Radionuclide therapy of neuroendocrine tumors

Andrew Mallia, Marco Maccauro, Ettore Seregni, Chiara Bampo, Carlo Chiesa, Emilio Bombardieri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Neuroendocrine tumors (NETs) are a group of tumors which frequently express somatostatin receptors (SSTRs) and represent 1 % of all neoplasms that may arise in the body. NETs of the gastro-entero-pancreatic tract (GEP NETs) and tumors of the sympatho-adrenal lineage are the most frequent tumors observed in clinical practice. Improved diagnostic techniques, both functional and anatomical, have resulted in an increased incidence of NETs. The term neuroendocrine defines cells that share common characteristics, such as the ability to take up and decarboxylate several amine precursors (APUD system), the absence of axons and synapses, the production of cell type-specific hormonal products and the demonstration of particular histopathological staining [1]. The variation in biological characteristics of these tumors poses considerable problems when deciding the optimal treatment strategies.

Original languageEnglish
Title of host publicationNuclear Medicine Therapy: Principles and Clinical Applications
PublisherSpringer New York
Pages57-83
Number of pages27
ISBN (Print)9781461440215, 1461440203, 9781461440208
DOIs
Publication statusPublished - Aug 1 2013

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mallia, A., Maccauro, M., Seregni, E., Bampo, C., Chiesa, C., & Bombardieri, E. (2013). Radionuclide therapy of neuroendocrine tumors. In Nuclear Medicine Therapy: Principles and Clinical Applications (pp. 57-83). Springer New York. https://doi.org/10.1007/978-1-4614-4021-5_4